The financials
BridgeBio Pharma, Inc. by the numbers
BridgeBio Pharma, Inc. (BBIO) reported revenue of $244M in Q2 2026 (quarter ended June 30, 2026), up 120% from the same quarter a year earlier. That came with a gross margin of 94% and net loss of $156M. For the full year FY2025, revenue was $502M (+126% year on year) and net income −$733M. Its largest product in 2026-Q2 was License Services And Royalty at $18M, 45% of the disclosed total, just ahead of Royalty at 40%.
| Income statement | Q2 2026 | Q2 2025 | Change |
|---|---|---|---|
| Revenue | $244M | $111M | +120% |
| Gross profit | $229M | $107M | +114% |
| Operating income | −$107M | −$134M | n/a |
| Net income | −$156M | −$184M | n/a |
| Diluted EPS | −$0.78 | −$0.95 | n/a |
| Product | Revenue | Share |
|---|---|---|
| License Services And Royalty | $18M | 45% |
| Royalty | $15M | 40% |
| License And Service | $5.8M | 15% |
Business Segments
Revenue split by product segment, from SEC XBRL filings.
Latest period: Q2 2026Total $38.8M (+60%)
Royalty grew +850% year on yearLicense And Service -84% year on year
Segment Latestquarter on quarteryear on year
- License Services And Royalty$17.6M$17.6MQoQ +71%year on year -+71%-
- Royalty$15.4M$15.4MQoQ +62%year on year +850%+62%+850%
- License And Service$5.8M$5.8MQoQ +31%year on year -84%+31%-84%
- Attruby--QoQ -year on year ---
- License And Services--QoQ -year on year ---
- Net Product--QoQ -year on year ---
- Royalty--QoQ -year on year ---